BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34579194)

  • 1. COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.
    Jeong SK; Heo YK; Jeong JH; Ham SJ; Yum JS; Ahn BC; Song CS; Chun EY
    Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of TLR1/2 and TLR3 ligands enhances CD4(+) T cell longevity and antibody responses by modulating type I IFN production.
    Lee BR; Jeong SK; Ahn BC; Lee BJ; Shin SJ; Yum JS; Ha SJ
    Sci Rep; 2016 Sep; 6():32526. PubMed ID: 27580796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
    Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
    J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
    Sui Y; Li J; Zhang R; Prabhu SK; Andersen H; Venzon D; Cook A; Brown R; Teow E; Velasco J; Greenhouse J; Putman-Taylor T; Campbell TA; Pessaint L; Moore IN; Lagenaur L; Talton J; Breed MW; Kramer J; Bock KW; Minai M; Nagata BM; Lewis MG; Wang LX; Berzofsky JA
    JCI Insight; 2021 Apr; 6(10):. PubMed ID: 33908897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.
    S Arunachalam P; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Roltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Doyle-Meyer L; Bohm RB; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O Hagan DT; Most RV; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar M; King NP; Veesler D; Pulendran B
    bioRxiv; 2021 Feb; ():. PubMed ID: 33594366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.
    Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; Dâ Aquino AI; Pulendran B; Kim PS; Appel EA
    bioRxiv; 2021 Aug; ():. PubMed ID: 33821276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
    Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
    EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered
    Liu B; Yin Y; Liu Y; Wang T; Sun P; Ou Y; Gong X; Hou X; Zhang J; Ren H; Luo S; Ke Q; Yao Y; Xu J; Wu J
    Engineering (Beijing); 2022 Jun; 13():107-115. PubMed ID: 34457370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
    Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines.
    Chen H; Wang L; Zhao X; Jiang H; Wu M; Ding Y; Jia X; Zhang Y; Li T; Zhang Y; Zhou W; Zheng P; Yang Y; Du J
    ACS Nano; 2024 Mar; 18(12):9160-9175. PubMed ID: 38478910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.